Top Markets
#1 Fake World Assets Fake World Assets +11.59%
#2 TENDIES TENDIES +4.80%
#3 GoPlus Security GoPlus Security +4.67%
#4 Everything Everything +3.70%
#5 TronBank TronBank +3.67%
#6 Janction Janction +3.26%
#7 Prom Prom +3.26%
#8 Tutorial Tutorial +3.00%
#9 DUSK Network DUSK Network +2.91%
#10 Bedrock Bedrock +2.68%
Coin of the day
Fake World Assets Fake World Assets
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Kineta, Inc. Kineta, Inc.

Kineta, Inc.

KA
Kedudukan dalam Saham #34153
Kineta, Inc. is a clinical-stage biotechnology firm dedicated to developing... Kineta, Inc. is a clinical-stage biotechnology firm dedicated to developing immunotherapies, with a focus on oncology, neuroscience, and biodefense applications. The company engages in partnerships with a variety of entities, including private companies, government bodies, and other industry stakeholders. Among its significant strategic collaborators are Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. Established in 2007, Kineta, Inc. was previously known as Lecura, Inc. and has its base of operations in Seattle, Washington.
Harga Saham
$0.617
Disegerakkan terakhir: 2024-10-14
Modal Pasaran
$6.13M
Perubahan (1 hari)
0.49%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Kineta, Inc. (KA)

Kategori

Healthcare
Pendapatan untuk Kineta, Inc. (KA)
Pendapatan pada Mar 2025 TTM: $-7.68M
Menurut laporan kewangan terkini Kineta, Inc., pendapatan semasa syarikat ialah $-7.68M. Pada tahun 2023, syarikat memperoleh pendapatan sebanyak $-14.08M, peningkatan berbanding pendapatan pada tahun 2022 yang berjumlah $-63.45M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Kineta, Inc. dari 2015 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
2026 (TTM) $-7.68M -55.17%
2024 $-17.13M 21.71%
2023 $-14.08M -77.82%
2022 $-63.45M 436.96%
2021 $-11.82M 66.16%
2020 $-7.11M -87.97%
2019 $-59.13M -4.38%
2018 $-61.83M 4.04%
2017 $-59.43M 59.63%
2016 $-37.23M 48.69%
2015 $-25.04M 0.00%
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -68,774.65%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -25,495.78%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -39,231.85%
BE